Science & Enterprise subscription

Follow us on Twitter

  • A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial p… https://t.co/iByygVnB9U
    about 16 hours ago
  • New post on Science and Enterprise: Covid-19 Drug Biotech Raises $300M in IPO https://t.co/zwkRakiFk5 #Science #Business
    about 17 hours ago
  • The Food and Drug Administration plans to use organ-on-chip models to test mechanisms for preventing Covid-19 infec… https://t.co/9zAfSK9Nnt
    about 22 hours ago
  • New post on Science and Enterprise: FDA to Use Lung Chip Model for Covid-19 Testing https://t.co/YGwasY1UUJ #Science #Business
    about 22 hours ago
  • Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among… https://t.co/bm7JdQ83hT
    about 2 days ago

Please share Science & Enterprise

Covid-19 Drug Biotech Raises $300M in IPO

Wall Street sign

A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock. . . . → Read More: Covid-19 Drug Biotech Raises $300M in IPO

FDA to Use Lung Chip Model for Covid-19 Testing

Emulate lung chip

The Food and Drug Administration plans to use organ-on-chip models to test mechanisms for preventing Covid-19 infections, and other processes. . . . → Read More: FDA to Use Lung Chip Model for Covid-19 Testing

Covid-19 Antibodies Cut Viral Load, Medical Visits

SARS-Cov-2 virus

Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among non-hospitalized Covid-19 patients. . . . → Read More: Covid-19 Antibodies Cut Viral Load, Medical Visits

200M Covid-19 Vaccine Doses Donated to Int’l Effort

Vaccine vials

Sanofi and GlaxoSmithKline are offering 200 million doses of their Covid-19 vaccine for a project devoted to making vaccines equitably available worldwide. . . . → Read More: 200M Covid-19 Vaccine Doses Donated to Int’l Effort

Novartis Gains Synthetic Protein Therapies for Covid-19

SARS-CoV-2 and cell

Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components. . . . → Read More: Novartis Gains Synthetic Protein Therapies for Covid-19

Lilly, NIH Halt Covid-19 Antibody Therapy Trial

Stop signs graphic

Drug maker Eli Lilly and National Institutes of Health are stopping a clinical trial testing a synthetic antibody to treat hospitalized Covid-19 patients. . . . → Read More: Lilly, NIH Halt Covid-19 Antibody Therapy Trial

Infographic – Covid-19 Cases Reach New Highs

Global Covid-19 cases

New Covid-19 infection cases are surging again in most parts of the world, with numbers accelerating fastest in Europe and the Americas. . . . → Read More: Infographic – Covid-19 Cases Reach New Highs

Roche Gains Covid-19 Oral Drug Candidate

Pills and capsules

Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a oral drug, rather than an infusion. . . . → Read More: Roche Gains Covid-19 Oral Drug Candidate

Covid-19 Vaccine Challenge Trial Underway

Syrine ingloved hand

Researchers in the U.K. are beginning a human challenge trial that intentionally exposes volunteers to SARS-CoV-2 viruses to test candidate vaccines. . . . → Read More: Covid-19 Vaccine Challenge Trial Underway

Myeloma Drug Shown to Treat Covid-19 Patients

Sea squirt

Results from an early clinical trial show a drug designed to treat multiple myeloma also reduces viral loads and hospital stays of patients with Covid-19 infections. . . . → Read More: Myeloma Drug Shown to Treat Covid-19 Patients